Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Clinical evidence shows these drugs reduce weight by 15-22% over 68 weeks and improve HbA1c levels in type 2 diabetes patients by 1.5-2.0 percentage points
Wettergren, A
The market is expanding at a CAGR of 28.54% between 2025 and 2034
Originally approved under the brand name Mounjaro for Type 2 diabetes management, Tirzepatide has since been approved under Zepbound for chronic weight management in adults
US$ 28.54
US$ 28.32
US$ 28.70
US$ 27.33
US$ 29.53
US$ 23.89
US$ 26.95
US$ 21.45
US$ 20.94
US$ 20.18
US$ 29.87
US$ 22.23
US$ 28.83
US$ 25.75
